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Objective: to evaluate immunotherapy as a means of improving peripheral blood flow in chronic leprosy patients.
Design: this was a double-blind, randomised, placebo-controlled, clinical trial.
Materials: heat-killed Mycobacterium vaccae 1 mg plus 0.02 mg Tuberculin protein per 0.1 ml dose in borate buffer, with
saline as placebo. Those studied were 92 long-treated residents of a leprosy centre in Iran, 10 of their healthy children and 10
staff members. Evaluation employed the Perimed PF2, Laser±Doppler Flowmeter, a platinum skin thermistor, and a thermal
sensibility tester.
Methods: single intradermal injections of test or placebo were given to 103 patients 18 months before the blinded
evaluation. Fingerpulp blood flux was measured in controlled conditions and vasomotor reflexes and skin sensation to
touch, pain and heat were evaluated in 45 and 47 patients in the placebo and M. vaccae groups, respectively, and in
20 healthy control persons.
Results: Laser±Doppler flux, skin temperature, vasomotor reflexes and sensation were impaired in leprosy patients.
Immunotherapy improved (p50.05) Laser±Doppler flux, skin temperature and temperature sensation.
Conclusions: immunotherapy, given 18 months earlier, significantly improved blood flow and temperature sensation, in
fully-treated, chronic, leprosy patients. The same principles might be employed in other conditions of reduced peripheral
blood flow.
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leprosy.
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An immunotherapeutic based on killed Mycobacterium
vaccae is undergoing investigation in the treatment of
leprosy1±4 and of vascular diseases.5,6 M. vaccae com-
bines adjuvant activity regulating T helper cell matur-
ation, with antigens important in immune regulation.7Please address correspondence to: J. L. Stanford, Department of
Medical Microbiology, Royal Free and University College Medical
school, Windeyer Institute of Medical Sciences, 46 Cleveland Street,
London W1T 4JF, U.K.
1078±5884/02/030202 07 $35.00/0 # 2002 Elsevier Science Ltd. AlIt is a rich source of group i, common, mycobacterial
antigens,8 including the mycobacterial 65 and
70 kiloDalton (kDa) heat-shock proteins (hsp). Like
M. leprae, M. vaccae lacks both groups ii and iii antigens
and has its own species-specific, group iv antigens.8,9
Small studies of the efficacy of killed M. vaccae in
immunotherapy of leprosy have been reported and it
has been shown that the addition of one tenth of a skin
test dose of new Tuberculin may improve its efficacy
in this disease.1 In a study of immunotherapy with
M. vaccae in leprosy patients, improved resolution
of pre-existing anterior uveitis has been observed,10l rights reserved.
Fig. 1. Flow diagram showing the progression of patients through
the study.
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together with observations of improvements in
Raynaud's disease in otherwise healthy persons, led
to our study.
Chronic, long-treated, leprosy patients often show
a progressive deterioration in peripheral microcircula-
tion and in nerve function,11 with serious conse-
quences such as ulcers on the feet, progressive
clawing of the hands12 and destruction of bone13 of
face, hands and feet, as well as soft tissue lesions of the
face and body. Microcirculatory impairment has been
shown to be an important factor in pathology and to
complicate prognosis, especially in patients of long-
standing, resulting in disproportionately cold fingers
at high ambient temperatures.14,15
Eighteen months after suitable patients had been
randomized to receive M. vaccae or placebo,16 their
fingerpulp circulation and that of an healthy control
group were compared by a number of parameters.
Materials and Methods
Immunotherapy and placebo
The immunotherapeutic consisted of an heat-killed
(autoclaved for 15 min at 121 C) suspension of
M. vaccae strain NCTC 11659 grown on Sauton's
medium, solidified with 1.3% agar. The suspension
contained 10 mg wetweight of bacilli in 1 ml of borate
buffered saline (pH 8) to which 0.1 ml new Tuberculin
(2 mg/ml) was added shortly before administration.1,16
Intradermal injection of 0.1 ml of the thoroughly
shaken immunotherapeutic or of saline as placebo,
were given over the left deltoid muscle.
Setting
The leprosy colony at Baba Baghi was set up some 80
years ago in a fertile, isolated and enclosed valley a
few miles from the city of Tabriz in Iranian Azerbaijan.
Modern Baba Baghi consists of a hospital with 60
beds, with an out-patient department, surrounded by
a village of patients houses and flats with supporting
facilities. Approximately 200±250 patients live there
with their healthy children and grandchildren.
Subjects and study design
Eighteen months before our study 103 patient volun-
teers under the age of 65 were skin tested with 4 new
tuberculins (Tuberculin, Leprosin A, Scrofulin and
Vaccin).17 On the basis of their responses to theseand their clinical type of leprosy, they were random-
ised into two groups to receive an injection of the
immunotherapeutic or of placebo.16 In general, hos-
pitalised patients with beds on the left sides of wards
were given the immunotherapeutic and those on the
right were given the placebo. Non-hospitalised
patients were seen in the clinic and alternate patients
received immunotherapy or placebo. This was done
taking care that similar numbers of paucibacillary
patients fell into each group and that patients making
`` Koch-type'' responses to Tuberculin were evenly
represented.18 Patients did not know which injection
they received and the injector (JLS) was not present at
the time of follow-up. Figure 1 gives the participant
flow in the study.
Of the original 103 patients, 47 M. vaccae and 45
placebo recipients were resident at the hospital and
available for testing when our clinical measurements
were carried out. All gave informed consent to have
measurements with the Laser±Doppler Flowmeter
and for their vasomotor reflexes and finger sensation
to be assessed. Assessments were made by an oper-
ator (NCA) who was unaware of which study treat-
ment the subjects had received. Twenty healthy
persons volunteered to be controls; 10 were adult
offspring of patients and resident at Baba Baghi and
10 were members of staff.
At the end of our investigation, an injection of
M. vaccae was offered to the placebo recipients, and
accepted by most.
Estimate of blood flow
The Laser±Doppler Flowmeter (Model PF2, Perimed,
Stockholm, Sweden) measures the movement of
erythrocytes in the most superficial 1 mm of skinEur J Vasc Endovasc Surg Vol 24, September 2002
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reflected out of the tissue.19 Internally standardised,
the instument gives an integrated measurement of
microvascular blood flow related to the product of the
number of moving erythrocytes and their mean vel-
ocity: Laser±Doppler flux, expressed in volts.20,21 The
fibre-optic tip of the flowmeter was attached to the
pulp of the distal phalanx by a probe holder fixed with
double-sided adhesive tape ensuring optimal align-
ment between sensor head and skin surface. The out-
put signal was recorded continuously during the
period of observation on a chart recorder calibrated
to a full scale deflection of 10 volts. Flowmeter settings
were as described previously.14 The fingerpulp was
investigated because its abundant arteriovenous ana-
stomoses are under strict autonomic control.22 Skin
sympathetic reflexes were assessed from the change
in Laser±Doppler flux following a deep inspiratory
gasp or a contralateral challenge of plunging the
hand into cold water.13,14,23
Measurement of fingerpulp skin temperature
A platinum skin thermistor was used to measure skin
surface temperature in the manner described previ-
ously.14 The probe (Model 4098, 9 mm diameter,
Yellow Springs Instrument Co. Inc., OH, U.S.A.) was
held in close contact with the skin with a single strip
of Millipore adhesive tape. A stable temperature was
generally achieved after 5 minutes contact with the
skin of the fingertip pulp. The same sensor was used
to measure room temperature near the subject during
experimentation.
Sensory testing
Sensation in the upper limb was tested for light touch
with cotton wool, for sharp touch or pain by pin prick
and for temperature sensation with a thermal sensibil-
ity tester.14 Three sites were tested on the palmar
aspect of each finger, including the fingerpulp. The
results were recorded on a three-point scale:
1 absent or consistently mistaken; 2partial sensa-
tion (i.e. variable positive and negative results from
site to site on a finger); 3unimpaired sensation. For
convenience of analysis the summary result on each
subject was the mean score (out of 3) for each type of
sensation tested.
Experimental protocol
Subjects were seated comfortably with the forearm
and hand resting on a table at heart level at an ambientEur J Vasc Endovasc Surg Vol 24, September 2002temperature of 25±29 C maintained by a paraffin
stove in the experimentation room. Ambient tempera-
ture was measured by the thermistor, described above,
situated within 25 mm of the subject at the same level
as the hands. These conditions induce near maximal
peripheral vasodilatation and stable blood flow
through the fingertips in healthy subjects. Each subject
was allowed to equilibrate under these conditions for
at least 15 min before measurements were started. All
four fingers were studied on both the right and left
hands. In some patients one or more fingers were
missing, or too deformed for measurements to be
carried out.
Measurements of sensation were made in the order;
light touch, sharp touch and temperature discrimina-
tion. Skin temperature was then recorded and, lastly,
Laser±Doppler flux was measured.
Outcome measures
The primary outcome measure was the Laser±Doppler
flux measurement expressed in volts. Secondary out-
come measures were the fingerpulp skin temperature,
the vasomotor reflex responses and the measurements
of sensation.
Statistical analysis
All analyses were performed using SPSS for Windows
(ver 6.1, SPSS, Chicago). Differences between patients
and control subjects and between patients receiving
M. vaccae or placebo were assessed for each measured
parameter using two-way ANOVA taking intra-
individual differences between fingers into account.
Differences in the responses to skin testing between
groups were assessed using the Mann±Whitney
U-test.
To detect a difference of 0.8 volts of Laser±Doppler
flux (approx. 20% of mean flux in groups of leprosy
patents14,15), and assuming a standard deviation of
1.5 volts,15 it was calculated that at least 44 patients
would be required for each group assuming a power
of 80% at the 0.05 level of significance.
Results
There were no significant differences between the
patient groups in age, sex, duration of stay in Baba
Baghi, in the proportion with lepromatous disease or
in their responses to skin tests prior to administration
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patient groups were significantly older than the
healthy volunteers in the control group (p5 0.05).
Table 2 shows the effect of leprosy, with or without
immunotherapy, on Laser±Doppler flux, fingerpulp
skin temperature, sympathetic vasomotor reflexes
and touch, pain and temperature sensation. Since the
95% confidence limits for the 20 healthy control
subjects were 3.1±10.0 volts for Laser±Doppler flux
(mean 6.6) and 31.0±35.0 C for skin temperature
(mean 33.1 C), leprosy patients fingers with mean
flux measurements of less than 3.1 volts and fingertipTable 2. The effect of immunotherapy with M. vaccae or
Doppler flux, temperature, vasomotor reflexes in res
estimates of sensory function.
Control
No. of subjects 20
Fingers tested 160/160
Room temp in C 25.4 (23.1±
LDFlux in Volts 6.4 (3.1±12
Percent fingers with impaired LDFlux 1
Percent fingers with LDFlux5 1 volt 0
Fingertip skin temperature in C 33.1 (29.3±
Percent fingers with low skin temp 4
Inspiratory Gasp (%) 82 (0±100)
Cold Challenge (%) 81 (0±100)
Sensory Score
Light Touch 3.0 (3±3)
Sharp Touch 3.0 (3±3)
Temperature 3.0 (3±3)
Mean of the air temperatures when the members of ea
yDifference from control group assessed by ANOVA (p5
{Difference between placebo and M. vaccae groups asses
Table 1. Basic characteristics of patients and controls, a
A, Vaccin and Scrofulin carried out immediately be
Data are shown as medians (range).
Contr
Subjects (n) 20
Age (years) 25.5 (1
Years in Baba Baghi














Median diameter of induration of 2 mm or more at 72 h
yDifference from control group (p5 0.05).skin temperature less than 31.0 C were considered
impaired for the purposes of analysis. Laser±Doppler
flux, skin temperature and temperature sensation
were greater (p5 0.05) in the immunotherapy group
than in the placebo recipients. In the placebo group
45% of all fingers had impaired Laser±Doppler flux
values (53.1 volts) and 42% had impaired skin tem-
peratures (531.0 C) whereas these values were 33
and 31% respectively for the immunotherapy group.
All measurements were significantly impaired in the
leprosy patient groups compared with the healthy
control persons (p5 0.05).placebo on measurements (median [range]) of Laser±




28.9) 24.8 (22.1±29.6) 25.4 (23.1±28.9)
.3) 3.6 (0.1±12.6) y 4.5 (0.1±14.1) y z
45 y 33 y z
25 y 13 y z
35.4) 31.8 (22.6±35.2) y 32.1 (20.6±34.9) y z
42 y 31 y z
24 (0±90) y 27 (0±90) y
0 (0±90) y 0 (0±90) y
3.0 (0±3) y 3.0 (0±3) y
3.0 (0±3) y 3.0 (0±3) y
2.0 (0±3) y 3.0 (0±3) y z
ch group were tested.
0.05, multiple range test).
sed by ANOVA (p5 0.05, multiple range test).
nd the results of skin tests with Tuberculin, Leprosin
fore administration of immunotherapy or placebo.
ol Placebo M. vaccae
45 47
6±70) 47 (25±65) y 47.5 (16±72) y
23 (3±38) 23 (8±40)
64 62
30/44 (68) 26/46 (57)
10 (3±22) 6.5 (2±15)
9/44 (21) 12/46 (26)
7 (3±15) 3 (2±14)
12/44 (27) 15/46 (33)
6 (4±14) 9 (3±17)
14/44 (32) 15/46 (33)
4.5 (2±9) 4.5 (2±18)
.
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receiving immunotherapy had significantly higher
Laser±Doppler flux values than those receiving pla-
cebo (mean values 4.59 vs 3.91 volts, representing 27%
vs 42% impaired fingers respectively in each group).
Tuberculoid patients showed a similar difference
between immunotherapy and saline groups but this
did not reach a level of significance (mean values 4.06
vs 3.5 volts).
Discussion
Leprosy, a disease caused by infection with Myco-
bacterium leprae, is associated with major perturbation
of the immune response. This results in a number of
different clinical presentations ranging over a well-
established immunopathological spectrum.24 The dis-
ease predominantly affects skin and nerves, but many
tissues are secondarily affected. At the multibacillary,
or lepromatous, end of the spectrum large numbers of
bacilli are demonstrable in the tissues and the cellular
immune response to M. leprae antigens is suppressed,
though high titres of antibodies are frequently present.
At the paucibacillary, or tuberculoid, end of the spec-
trum, bacilli can be very hard to find and an abnormal
cellular immune hyper-responsiveness is observed
with lower antibody levels. Leprosy bacilli combine
antigens sharing major amino-acid sequence homolo-
gies with human tissue antigens, including the stress
proteins of mitochondrial origin, with potent myco-
bacterial adjuvants. Thus autoimmune phenomena
involving many tissues complicate the disease, espe-
cially in its chronic forms. Despite modern chemother-
apy with effective antibacterial agents eliminating
living bacilli, tissue damage may continue for the
rest of the patient's life, largely due to autoimmune
consequences of the disease. The continued peripheral
vascular deterioration is an important part of this
post-infective leprosy syndrome.
The present study is the first to describe the effect of
immunotherapy with M. vaccae on peripheral micro-
circulation. Our finding that this resulted in higher,
though still abnormally low, fingerpulp blood flows
was unexpected given a disease and treatment dur-
ation in the patients in excess of 20 years. There is also
evidence that the effect occurs across disease classifi-
cation, lepromatous patients receiving immunother-
apy had significantly higher Laser±Doppler flux than
those receiving placebo and tuberculoid patients
showed a similar trend between treatment groups.
The lack of pre-treatment measurements of microcir-
culation and sensation makes the results less impres-
sive than they might have been, yet they agree withEur J Vasc Endovasc Surg Vol 24, September 2002the reported reduction in anterior uveitis seen in these
and similar patients after treatment with M. vaccae.10
Many studies have addressed the immune situation
in active leprosy but very little has been done on long-
treated chronic disease such as that of our study
group. In active lepromatous disease there is an excess
of T helper cell type 2 (Th2) activity with predomin-
antly Th2-associated antibody production. Unlike the
situation in pulmonary tuberculosis, the toxicity of
tumour necrosis factor (TNF) is rarely apparent.
Active tissue necrosis is not seen except during reac-
tive episodes known as erythema nodosum leprosum
(ENL) and Lucio's phenomenon of which local endar-
teritis is the major lesion. In tuberculoid leprosy both
Th1 and Th2 lymphocytes infiltrate the lesions giving
rise to granulomas which rarely necrose. Sudden
changes in the intensity of cellular immunity are
thought to be the cause of reversal reactions in which
inflammation of peripheral nerves and their subse-
quent fibrosis is an important feature. Again, it may
be that arteriolar and capillary inflammation is the
underlying lesion.
The Laser±Doppler flux method of microcirculatory
monitoring has been found reproducible for the detec-
tion of differences in fingerpulp blood flow and skin
sympathetic reflexes between groups of leprosy
patients (new vs treated; lepromatous vs tuberculoid)
and also between patients and healthy subjects.14
Iranian patients show a similarly reduced peripheral
flow giving support to the use of this technique as
a sensitive monitor of changes in their peripheral
circulation.12,14
The cause of reduced peripheral blood flow in lep-
rosy patients is uncertain, and regulating factors may
include sympathetic vasoconstrictor activity, intrinsic
vascular tone, circulating hormones and haemorheo-
logical factors. Histopathological evidence shows that
the smaller blood vessels can be damaged25±28 and
that functional changes such as impaired blood flow
in terminal vascular loops13 or tortuosity of the
arteries of the hands26 occur. There is no evidence,
however, of large vessel disease, such as atheroscler-
osis per se, in leprosy patients. The demonstration,
in both Indian and Iranian leprosy patients,14 that
reduced flow often co-exists with local sensory
loss suggests that nerve damage11 is linked to
chronic inflammation and functional deterioration
of vasculature.
Vascular deterioration in leprosy may be due to
continuing sub-chronic vasculitis, possibly associated
with immune complex formation29 during clearance
of residual bacteria. It may also be due to persisting
antibodies to stress proteins induced by the leprosy
bacilli continuing to act as autoantibodies long after
Immunotherapy for Fingerpulp Blood Flow in Leprosy 207the bacilli have gone. Such antibodies are known to be
associated with vasculitis and the laying down of
atheroma.30,31 A significant reduction in the titre of
antibodies to the 65 kDa hsp of BCG following
immunotherapy with M. vaccae has been reported
from our study group of patients.32 Whatever the
mechanism by which it acted, immunotherapy with
M. vaccae has partly reversed the process or prevented
further deterioration of blood flow in fully treated
leprosy patients, an observation that may be applic-
able to many conditions other than leprosy.
Immunotherapy with M. vaccae has been investi-
gated in a whole series of diseases in which dys-
regulation of T helper cell maturation has occurred.
These include tuberculosis,33±35 asthma,36,37 atopic
dermatitis,38 psoriasis,39 HIV infection40 and a range
of different cancers.41±43 A very recent publication has
shown that, in mice at least, an injection of heat-killed
M. vaccae stimulates the production of regulatory T
cells passageable between animals and capable of
regulating specific allergen induced eosinophilia.44 It
is highly likely that many of the activities recorded for
M. vaccae are related to the induction of these cells.
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